Rosehip vs Tirzepatide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Rosehip vs Tirzepatide: Tirzepatide has the stronger overall evidence (7.8 vs 5/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Tirzepatide Edges Ahead

Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Rosehip1 win

Tirzepatide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Rsh5.0

Rosehip

Too few graded studiesHigh safety

Tir7.8

Tirzepatide

Too few graded studiesLimited safety

Evidence

Evidence Score

5/10

Studies: 17

Meta-analyses: 1

Level: Moderate

Evidence Score

Best7.8/10

Studies: 133

Meta-analyses: 42

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Joint pain & arthritisToo few graded studies7
Safety profileToo few graded studies1

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies80
Glycemic & metabolic controlToo few graded studies53
Heart & blood pressureToo few graded studies20

Dosage & timing

Recommended Dosage:

5g daily of standardized rosehip powder (the dose used in the OA trials)

Warnings

Benefit on OA pain is modest and most pivotal trials were manufacturer-funded
Not a substitute for medical management of osteoarthritis

Best Time:

With meals

Take with food

Best Form:

Standardized rosehip powder (GOPO-standardized)

Recommended Dosage:

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.
Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.
A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.
FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.
Not for cosmetic or off-label use without a medical indication and supervision.
May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.
Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

Safety

High safetyBest

Drug Interactions:

Warfarin / anticoagulants (mild)

Side Effects:

Mild GI upset / loose stools

Contraindications:

Known allergy to Rosa species
Caution with high doses of vitamin C in those prone to oxalate kidney stones

Limited safety

Drug Interactions:

Oral contraceptives (moderate)
Insulin and sulfonylureas (moderate)
Oral medications generally (moderate)

Side Effects:

NauseaDiarrheaVomiting

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

What you'll notice

🦵 Reduced osteoarthritis painpositive

3 weeks to 3 months

💊 Lower rescue-medication usepositive

3-12 weeks

ℹ️ Effect is modestneutral

Throughout use

🩸 Strong glycemic controlpositive

Weeks to months

⚖️ Large weight losspositive

Months (dose-escalated over ~20 weeks)

😴 Reduced sleep-apnea severitypositive

Weeks to months

🤢 GI side effects (common)negative

Mostly during titration

Key studies

Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients?--a meta-analysis of randomized controlled trials.

Osteoarthritis Cartilage (2008) · Meta analysis · n=287

Pooled three RCTs (287 patients, median 3-month duration)

A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial.

Scand J Rheumatol (2005) · Crossover · n=94

94 patients, randomized double-blind placebo-controlled crossover, 5g/day for 3 months

The clinical effectiveness of rosehip powder in patients with osteoarthritis. A systematic review.

MMW Fortschr Med (2007) · Systematic review

Systematic review of two double-blind RCTs (N=100 and 112, Jadad score 5)

All Rosehip studies

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=1879

Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med (2022) · Rct · n=2539

72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

N Engl J Med (2025) · Rct · n=751

Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide

All Tirzepatide studies

Frequently asked questions

Is Rosehip better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 5/10) and wins in 2 of 3 categories.

Can I take Rosehip and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Iron vs Rosehip Rosehip vs Whey Protein Rosehip vs Semaglutide Semaglutide vs Tirzepatide Liraglutide vs Tirzepatide Thiamine vs Tirzepatide

Still deciding between Rosehip and Tirzepatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Rosehip details Tirzepatide details

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.

Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.

A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.

FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.

Not for cosmetic or off-label use without a medical indication and supervision.

May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.

Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.